Intended for healthcare professionals


BMA annual meeting: Pregabalin must be made a controlled drug, BMA says

BMJ 2017; 357 doi: (Published 29 June 2017) Cite this as: BMJ 2017;357:j3151
  1. Tom Moberly
  1. UK Editor, BMJ

Pregabalin should be reclassified as a controlled drug to tackle widespread problems of misuse and addiction, the BMA has said.

Delegates at the BMA’s annual representative meeting in Bournemouth on 28 June voted in favour of a motion saying that the BMA should “lobby the appropriate authorities to make pregabalin a controlled drug.”

Pregabalin is currently a prescription only drug and is licensed for the treatment of neuropathic pain and …

View Full Text

Log in

Log in through your institution


* For online subscription